121 related articles for article (PubMed ID: 2740355)
1. 1,25-Dihydroxyvitamin D3 and the regulation of human cancer cell replication.
Eisman JA; Koga M; Sutherland RL; Barkla DH; Tutton PJ
Proc Soc Exp Biol Med; 1989 Jul; 191(3):221-6. PubMed ID: 2740355
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1,25-dihydroxyvitamin D3 on cell-cycle kinetics of T 47D human breast cancer cells.
Eisman JA; Sutherland RL; McMenemy ML; Fragonas JC; Musgrove EA; Pang GY
J Cell Physiol; 1989 Mar; 138(3):611-6. PubMed ID: 2925799
[TBL] [Abstract][Full Text] [Related]
3. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells.
Koga M; Eisman JA; Sutherland RL
Cancer Res; 1988 May; 48(10):2734-9. PubMed ID: 2834048
[TBL] [Abstract][Full Text] [Related]
4. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
5. Effect of 1,25-dihydroxyvitamin D3 on mouse mammary tumor (GR) cells: evidence for receptors, cellular uptake, inhibition of growth and alteration in morphology at physiologic concentrations of hormone.
Gross M; Kost SB; Ennis B; Stumpf W; Kumar R
J Bone Miner Res; 1986 Oct; 1(5):457-67. PubMed ID: 2845731
[TBL] [Abstract][Full Text] [Related]
6. 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects.
Wang Q; Lee D; Sysounthone V; Chandraratna RAS ; Christakos S; Korah R; Wieder R
Breast Cancer Res Treat; 2001 May; 67(2):157-68. PubMed ID: 11519864
[TBL] [Abstract][Full Text] [Related]
7. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
8. Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression.
Sebag M; Henderson J; Rhim J; Kremer R
J Biol Chem; 1992 Jun; 267(17):12162-7. PubMed ID: 1318311
[TBL] [Abstract][Full Text] [Related]
9. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
10. Involvement of endogenously produced 1,25-dihydroxyvitamin D-3 in the growth and differentiation of human keratinocytes.
Matsumoto K; Azuma Y; Kiyoki M; Okumura H; Hashimoto K; Yoshikawa K
Biochim Biophys Acta; 1991 May; 1092(3):311-8. PubMed ID: 1646640
[TBL] [Abstract][Full Text] [Related]
11. Influence of 1,25-dihydroxyvitamin D3 on cultured osteogenic sarcoma cells: correlation with the 1,25-dihydroxyvitamin D3 receptor.
Dokoh S; Donaldson CA; Haussler MR
Cancer Res; 1984 May; 44(5):2103-9. PubMed ID: 6324995
[TBL] [Abstract][Full Text] [Related]
12. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
13. Effects of vitamin D metabolites on proliferation and differentiation of cultured human epidermal keratinocytes grown in serum-free or defined culture medium.
Itin PH; Pittelkow MR; Kumar R
Endocrinology; 1994 Nov; 135(5):1793-8. PubMed ID: 7956903
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites.
Frampton RJ; Omond SA; Eisman JA
Cancer Res; 1983 Sep; 43(9):4443-7. PubMed ID: 6307514
[TBL] [Abstract][Full Text] [Related]
15. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Ly LH; Zhao XY; Holloway L; Feldman D
Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
[TBL] [Abstract][Full Text] [Related]
16. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cell growth, differentiation, and production of interleukin-3 by 1 alpha,25-dihydroxyvitamin D3 in the murine myelomonocytic leukemia cell line WEHI-3.
Abe J; Moriya Y; Saito M; Sugawara Y; Suda T; Nishii Y
Cancer Res; 1986 Dec; 46(12 Pt 1):6316-21. PubMed ID: 3490908
[TBL] [Abstract][Full Text] [Related]
18. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3.
Eisman JA; Barkla DH; Tutton PJ
Cancer Res; 1987 Jan; 47(1):21-5. PubMed ID: 3024816
[TBL] [Abstract][Full Text] [Related]
19. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; Birkenhäger JC; van Leeuwen JP
Eur J Cancer; 1996 May; 32A(5):842-8. PubMed ID: 9081364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
